baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Goldman Sachs Knock-Out ABBV/ DE000GG3KH70 /

25/07/2024 11:08:09	Chg.+0.25	Bid11:26:43	Ask11:26:43	Underlying	Strike price	Expiration date	Option type
2.81EUR	+9.77%	2.81 Bid Size: 5,000	2.86 Ask Size: 5,000	AbbVie Inc	204.076 USD	31/12/2078	Put

GlobeNewswire 01/07 Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

GlobeNewswire 01/07 OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in A...

GlobeNewswire 28/06 NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

GlobeNewswire 28/06 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...

GlobeNewswire 28/06 Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease

GlobeNewswire 27/06 Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Ach...

GlobeNewswire 26/06 COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors

GlobeNewswire 25/06 CEREVEL (NASDAQ:CERE) STOCK ALERT: Cerevel’s $45 Per Share Deal is Being Investigated by BFA Law, Sh...

GlobeNewswire 24/06 OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell...

GlobeNewswire 22/06 CEREVEL (NASDAQ:CERE) INVESTOR ALERT: Cerevel’s $45 Per Share Offer is Being Investigated by BFA Law...

GlobeNewswire 21/06 Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest C...

GlobeNewswire 20/06 CEREVEL INVESTOR REMINDER: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? Contact BFA Law...

GlobeNewswire 20/06 OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of I...

GlobeNewswire 19/06 OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the B...

GlobeNewswire 19/06 Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

GlobeNewswire 18/06 CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...

GlobeNewswire 18/06 CEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoi...

GlobeNewswire 17/06 CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

GlobeNewswire 17/06 Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, B...

GlobeNewswire 15/06 CEREVEL STOCK NOTICE: Think $45 Per Share is Too Low for Cerevel (Nasdaq: CERE)? Contact BFA Law abo...

Newsfile Corp 13/06 BioMed X Launches New US Institute in New Haven, CT

GlobeNewswire 13/06 Anima Biotech to Present at the Society for Medicines Research’s Modulating RNA with Oligonucleotide...

GlobeNewswire 13/06 LifeSci Advisors Announces Appointment of Chris Howerton Ph.D.

GlobeNewswire 13/06 CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investi...

GlobeNewswire 13/06 What Employees at the Fortune Best Workplaces in New York, Chicago, Texas, and the Bay Area Value Mo...

Goldman Sachs Knock-Out ABBV/ DE000GG3KH70 /

If you wish to receive reply to your feedback, please provide your email address.